|
|||||
|
|
Phase II trial of piroxantrone in patients with recurrent and metastatic squamous cell carcinoma of the head and neck |
|
| Authors: | Sarah A. Taylor Jacqueline Benedetti David Schuller Stephen P. Richman Goronwy O. Broun Alexander Hantel |
| Affiliation: | (1) University of Kansas Medical Center, Kansas City, KS;(2) Southwest Oncology Group Statistical Center, Seattle, WA;(3) Ohio State University Health Care Center, Columbus, OH;(4) University of Miami School of Medicine, Miami, FL;(5) St. Louis University, St. Louis, MO;(6) Loyola University Stritch School of Medicine, Maywood, IL, USA |
| Abstract: | Summary Twenty-two patients with recurrent or metastatic squamous cell carcinoma of the head and neck were treated with piroxantrone 150 mg/m2 intravenously every 21 days. There were no objective responses. The 95% upper confidence bound for response is 15%. Primary toxicity was hematologic. |
| Keywords: | piroxantrone squamous cell of head and neck |
| 本文献已被 SpringerLink 等数据库收录！ | |